Wealth Enhancement Advisory Services LLC Takes $420,000 Position in LivaNova PLC $LIVN

Key Points

• Wealth Enhancement Advisory Services LLC has acquired a new position in LivaNova PLC, purchasing 9,097 shares valued at approximately $420,000 in the second quarter.
• Several hedge funds, including AQR Capital Management and Hotchkis & Wiley Capital Management, increased their holdings in LivaNova, indicating stronger institutional interest in the company.
• Analysts have mixed reactions to LivaNova's stock performance, with a consensus rating of "Moderate Buy" and a price target averaging $59.71.

Wealth Enhancement Advisory Services LLC purchased a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 9,097 shares of the company's stock, valued at approximately $420,000.

Other hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC lifted its holdings in shares of LivaNova by 111.7% during the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company's stock valued at $60,809,000 after purchasing an additional 829,115 shares in the last quarter. Nuveen LLC bought a new position in shares of LivaNova during the first quarter worth $30,954,000. Hotchkis & Wiley Capital Management LLC lifted its position in shares of LivaNova by 100.7% in the first quarter. Hotchkis & Wiley Capital Management LLC now owns 1,003,000 shares of the company's stock worth $39,398,000 after buying an additional 503,350 shares in the last quarter. LSV Asset Management boosted its stake in LivaNova by 278.3% during the first quarter. LSV Asset Management now owns 438,498 shares of the company's stock valued at $17,224,000 after buying an additional 322,598 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in LivaNova by 13.5% during the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company's stock valued at $104,755,000 after buying an additional 316,993 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a report on Wednesday, September 3rd. The Goldman Sachs Group set a $55.00 price target on shares of LivaNova and gave the company a "neutral" rating in a research note on Wednesday, October 1st. Barclays increased their price objective on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of LivaNova in a research report on Saturday, September 27th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $59.71.

LivaNova Trading Down 1.4%

Shares of NASDAQ LIVN opened at $52.63 on Tuesday. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -13.53 and a beta of 0.95. The business's 50 day moving average price is $52.84 and its 200-day moving average price is $45.60.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. The business had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business's revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.93 earnings per share. On average, sell-side analysts expect that LivaNova PLC will post 2.85 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.